Can we eliminate placebo in ALS clinical trials?

Wilson W. Bryan, Rebecca J. Hoagland, J. Murphy, Carmel Armon, Richard J. Barohn, Jessie C. Goodpasture, Robert G. Miller, Gareth J Parry, Jack H. Petajan, Mark A. Ross, Scott C. Stromatt, Jerry M. Belsh, Aron S. Buchman, Peter D. Donofrio, Andrew A. Eisen, Richard A. Gan, Laurie Gutmann, Steven H. Horowitz, Carlayne E. Jackon, Wendy S. JohnstonJohn J. Kelly, Raul N. Mandler, Janice M. Massey, Dawn McGuire, Daniel S. Newman, Robert M. Pascuzzi, Jack H. Petajan, Lawrence H. Phillips, Michael H. Rivner, Mark A. Rubin, Louis S. Russo, Stephen M. Sergay, Austin J. Sumner, Michael R. Swenson, Lawrence Teitel

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint Dive into the research topics of 'Can we eliminate placebo in ALS clinical trials?'. Together they form a unique fingerprint.

Medicine & Life Sciences